Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection is linked to a respiratory syndrome with altered pulmonary and alveolar function that can lead to acute respiratory insufficiency and even death [1]. The molecular determinants and the mechanism that link SARS coronavirus infection to the pulmonary pathology are unknown. The scientific-clinical picture is further complicated by the fact that, while human SARS CoVs presents heavy pathogenicity leading to death, other human CoVs, such as HCoV-OC43 and HCoV-229E, are less pathogenic and cause common colds and mild lower respiratory tract infections [2].
Here, we explore the issue based on the rationale that, following a pathogen infection, peptide commonalities between the pathogen and the human proteins might trigger cross-reactions and a pathologic autoimmune sequela that might contribute to explain the pathogen associated diseases. Accordingly, we started the present study by investigating the spike glycoproteins from both SARS-CoV-2 and HCoV-229E for peptide sharing with human surfactant and related proteins.
Pulmonary surfactant plays a fundamental role in the physiology of ventilation by lowering the surface tension at the respiratory air-liquid interface within the alveoli. Excessively high values of surface tension would lead to alveolar collapse thus making ventilation and gas exchange impossible. Surfactant is produced by alveolar type II cells, secreted into the alveolar space, and it consists of lipids and proteins. The phospholipid component (dipalmitoylphosphatidylcholine, DPPC) reduces the surface tension, and the protein component - surfactant protein A (SP-A), surfactant protein B (SP-B), and surfactant protein C (SP-C) - together with a network of additional proteins regulate surfactant homeostasis and metabolism and, importantly, contribute to maintain immunological homeostasis in the lung, attenuating both infection and inflammation [4].
For the present study, pentapeptides were used as sequence probes since a peptide grouping formed by five amino acid (aa) residues is an immune molecular determinant that 1) can induce highly specific antibodies, and 2) determines antigen-antibody specific interaction [5]. Peptide sharing between spike glycoproteins and human surfactant-related proteins was analyzed as extensively described in previous publications [3 and refs. therein]. In brief. Spike glycoprotein primary sequences were dissected into pentapeptides offset by one residue and each viral pentapeptide was analyzed for matches within human proteins that had been retrieved from UniProtKB database (http://www.uniprot.org/) [6] using ‘surfactant’ as keyword. Next, the shared pentaptides were analyzed for presence in spike glycoproteins-derived immunoreactive epitopes by using the IEDB Immune Epitope DataBase (IEDB) [7] to analyze the immunological potential of the peptide sharing. The final results are reported in Table 1 and Table S1 and show that.
Table 1.
Spike glycoprotein pentapeptidesa: |
Human Surfactant-Related Proteinsd [4] | |
---|---|---|
HCoV-229Eb | SARS-CoV-2c | |
– |
VLPPL LPPLL |
AA2BR. Adenosine receptor A2b. Highly and uniquely expressed in type II alveolar epithelial cells. Potent anti-inflammatory role |
GVPQP | VFLVL | ABCA3. ATP-binding cassette sub-family A member 3. Crucial role in the formation of the storage compartment for surfactant, the lamellar body, and the transport of phospholipids in it; can cause chronic interstitial lung diseases |
SIVSL ITGVP VELLK ELLKQ | HVNNS GIGVT NESLI |
ABCAC. ATP-binding cassette sub-family A member 12. ABCAC deficiency causes alveolar collapse and reduction of surfactant protein B |
IPFSL PFSLA | – | ADA2A. Alpha-2A adrenergic receptor. Dysfunctions of adrenoceptor mediated effects contribute to hyaline membrane syndrome, wet lung, bronchial asthma |
PFSLA | RRARS | ADA2C. Alpha-2C adrenergic receptor. Pathology: see above |
SQALQ | CSCLK | AGRF5. G-protein coupled receptor 116.Regulates lung surfactant homeostasis |
GPLCV | C1QR1. Receptor for pulmonary surfactant protein A (SP-A) | |
– | IYQTS | CREB1. Cyclic AMP-responsive element-binding protein 1. CREB activation mediates anti-inflammatory activity of DPPC, the major phospholipid in pulmonary surfactant |
RLAAL YTEVR VEKIH |
– | CKAP4. Cytoskeleton-associated protein 4. SP-A binding protein in alveolar type II cells |
– | FIEDL | DJC10. DnaJ homolog subfamily C member 10 aka ERdj5. Necessary for degradation of misfolded surfactant protein C |
AMTNI | LDSKT | EPAS1. Endothelial PAS domain-containing protein 1 aka endothelial hypoxia-inducible factor-2α. Required for the maintenance of airway microvasculature |
– | SNNSI | GATA6. Transcription factor GATA-6. Activates transcription of surfactant protein A |
— | SSVLH NATRF FSQIL LIRAA IRAAE RAAEI |
MY18A. Unconventional myosin-XVIIIa aka Surfactant protein receptor SP-R210. Expressed on the surface of type II pneumocytes; acts as a receptor of the surfactant-associated protein A that reduces T lymphocytes proliferation and maintains a state of hyporesponsiveness to prevent flooding of the air spaces with inflammatory cells |
QPLLL | – | NAPSA. Napsin-A. Involved in the C– and N-terminal processing of surfactant protein |
– | LVLLP VLLPL | NPT2A. Sodium-dependent phosphate transport protein 2A. Essential since alveolar epithelial type II cells need phosphate for surfactant synthesis |
LVLLP | NPT2B. Sodium-dependent phosphate transport protein 2B. Function: see above | |
SYGVV | – | P2RY2. P2Y purinoceptor 2. The P2Y2 purinergic signaling pathway ultimately triggers exocytosis of lamellar bodies by ATII cells |
LDTIQ | – | PCAT1. Lysophosphatidylcholine acyltransferase 1. Involved in phosphatidylcholine metabolism in pulmonary surfactant |
YTGSL | – | PEPA3. Pepsin A-3. Component of pulmonary surfactant |
LACAQ | – | PSPB. Pulmonary surfactant-associated protein B. Increases the collapse pressure of palmitic acid to nearly 70 millinewtons per meter. Involved in the structural organization of lamellar bodies |
DSVSA | DQLTP | RCN3. Reticulocalbin-3. RCN3 deficiency causes death at birth owing to failure of functional maturation of alveolar epithelial type II cells during alveogenesis. This immaturity of type II cells is associated with a dramatic reduction in surfactant protein A and D, a disruption in surfactant phospholipid homeostasis, and a disorder in lamellar body |
– | GKQGN | SFTPD. Pulmonary surfactant-associated protein D. Regulates innate immunity of the lung |
– | ALTGI EDDSE | TTF1. Transcription termination factor 1. Modulates surfactant protein-B and —C promoters in lung cells |
Pentapeptides present in coronavirus spike glycoprotein-derived immunoreactive epitopes are given bold.
Spike glycoprotein (Uniprot Accession: P15423) from HCoV-229E (NCBI:txid11137).
Spike glycoprotein (id = QHD43416.1) from SARS-CoV-2, isolate Wuhan-Hu-1 (GenBank: MN908947.3).
Human surfactant-related proteins are given by Uniprot names. Function/pathology data from www.uniprot.org, [4], and Omim and PubMed databases.
- quantitatively the peptide sharing of the two coronaviruses is similar, and both HCoV-229E and SARS-CoV-2 share many pentapeptides (19 and 24, respectively) with surfactant and related proteins,
- the peptide sharing between coronaviruses and surfactant-related proteins appears to be specific since none of the 43 shared pentapeptides described in Table 1 was found in infectious pathogens that do not cause lung disease such as rabies virus, rubella virus, hepatitis C virus, and human parvovirus B19. A paradigmatic control is parvovirus B19 that is transmitted through exposure to infected respiratory droplets, exhibits mild cold-like symptoms that are never linked to the virus [8], and associates with a wide spectrum of diseases — from erythema infectiosum and arthropathy to encephalopathy and autoimmune hepatitis — that does not include lung disorders [9].
-
-
the peptide sharing described in Table 1 is also coronavirus-specific since not a single pentapeptide shared with surfactant and related proteins is common to the two coronaviruses,
-
-
immunologically, the human vs SARS-CoV-2 peptide sharing is of high relevance with 13 out of the 24 shared pentapeptides to be found in 52 SARS-CoV-derived immunoreactive epitopes (Table 1 and Table S1). Instead, only one HCoV-229E pentapeptide (RLAAL) shared with the analyzed surfactant proteins is hosted in only one HCoV-derived epitope (Table 1 and Table S1).
Additionally, Pneumocystis carinii (NCBI:txid1408658), the pathogenicity of which is characterized by rapid onset and fast progression of severe pneumonia symptoms resulting in high mortality rate [10], was analyzed as control. P. carinii was found to contain 17 of the 24 pentapeptides shared between SARS-CoV-2 and surfactant molecules, ie, it contains EDDSE, FIEDL, FSQIL, GIGVT, GKQGN, IYQTS, LDSKT, LIRAA, LPPLL, LVLLP, NESLI, RAAEI, SNNSI, SSVLH, VFLVL, VLLPL, and VLPPL peptides. In other words, a high phenetic similarity - possibly indicating a similar pneumonia pathogenicity – exists between SARS-CoV-2 and P. carinii but not between the two coronaviruses.
To conclude. This letter addresses the issue of why SARS-CoV-2 attacks the respiratory system and reports on a vast peptide sharing between SARS-CoV-2 spike glycoprotein and surfactant-related proteins. Analyses using the Immune Epitope DataBase (IEDB) resource also show that many of the shared peptides are endowed with immunological potential. Given the caveat that the positive correlation of the pentapeptide sharing shown in Table 1 needs to be controlled by serologic validation, results suggest that immune responses following SARS-CoV-2 infection might lead to crossreactions with pulmonary surfactant and related proteins, and might contribute to the SARS-CoV-2-associated lung diseases. The data warn against using vaccines based on entire SARS-CoV-2 antigens to fight SARS-CoV infections, and highlight peptide uniqueness as a molecular concept for effective anti-CoV immunotherapy [3].
Funding
The Authors received no funding for this study.
Footnotes
Supplementary data to this article can be found online at https://doi.org/10.1016/j.clim.2020.108426.
Appendix A. Supplementary data
References
- 1.Wang Z., Yang B., Li Q., Wen L., Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clin. Infect. Dis. 2020 doi: 10.1093/cid/ciaa272. pii:ciaa272. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Satija N., Lal S.K. The molecular biology of SARS coronavirus. Ann. N. Y. Acad. Sci. 2007;1102:26–38. doi: 10.1196/annals.1408.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kanduc D., Shoenfeld Y. From anti-EBV immune responses to the EBV diseasome via cross-reactivity. Infect. Int. 2019;7:1–21. doi: 10.1055/s-0040-1715641. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Perez-Gil J. Structure of pulmonary surfactant membranes and films: the role of proteins and lipid-protein interactions. Biochim. Biophys. Acta. 1778;2008:1676–1695. doi: 10.1016/j.bbamem.2008.05.003. [DOI] [PubMed] [Google Scholar]
- 5.Kanduc D. Homology, similarity, and identity in peptide epitope immunodefinition. J. Pept. Sci. 2012;18:487–494. doi: 10.1002/psc.2419. [DOI] [PubMed] [Google Scholar]
- 6.UniProt Consortium UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 2019;47:D506–D515. doi: 10.1093/nar/gky1049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Vita R., Mahajan S., Overton J.A., Dhanda S.K., Martini S., Cantrell J.R. The immune epitope database (IEDB): 2018update. Nucleic Acids Res. 2019;47:D339–D343. doi: 10.1093/nar/gky1006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Heegaard E.D., Brown K.E. Human parvovirus B19. Clin. Microbiol. Rev. 2002;15:485–505. doi: 10.1128/CMR.15.3.485-505.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Broliden K., Tolfvenstam T., Norbeck O. Clinical aspects of parvovirus B19 infection. J. Intern. Med. 2006;260:285–304. doi: 10.1111/j.1365-2796.2006.01697.x. [DOI] [PubMed] [Google Scholar]
- 10.Sokulska K., Kicia M., Wesołowska M., Hendrich A.B. Pneumocystis jirovecii--from a commensal to pathogen: clinical and diagnostic review. Parasitol. Res. 2015;114:3577–3585. doi: 10.1007/s00436-015-4678-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.